263 related articles for article (PubMed ID: 38769556)
1. KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges.
Li CY; Wang W; Leung CH; Yang GJ; Chen J
Mol Cancer; 2024 May; 23(1):109. PubMed ID: 38769556
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
3. Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B.
Pippa S; Mannironi C; Licursi V; Bombardi L; Colotti G; Cundari E; Mollica A; Coluccia A; Naccarato V; La Regina G; Silvestri R; Negri R
Molecules; 2019 May; 24(9):. PubMed ID: 31060229
[No Abstract] [Full Text] [Related]
4. MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
Denis H; Van Grembergen O; Delatte B; Dedeurwaerder S; Putmans P; Calonne E; Rothé F; Sotiriou C; Fuks F; Deplus R
Mol Biosyst; 2016 Feb; 12(2):404-13. PubMed ID: 26621457
[TBL] [Abstract][Full Text] [Related]
5. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
6. JARID1 Histone Demethylases: Emerging Targets in Cancer.
Harmeyer KM; Facompre ND; Herlyn M; Basu D
Trends Cancer; 2017 Oct; 3(10):713-725. PubMed ID: 28958389
[TBL] [Abstract][Full Text] [Related]
7. Structure of the Arabidopsis JMJ14-H3K4me3 Complex Provides Insight into the Substrate Specificity of KDM5 Subfamily Histone Demethylases.
Yang Z; Qiu Q; Chen W; Jia B; Chen X; Hu H; He K; Deng X; Li S; Tao WA; Cao X; Du J
Plant Cell; 2018 Jan; 30(1):167-177. PubMed ID: 29233856
[TBL] [Abstract][Full Text] [Related]
8. KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.
Hinohara K; Wu HJ; Vigneau S; McDonald TO; Igarashi KJ; Yamamoto KN; Madsen T; Fassl A; Egri SB; Papanastasiou M; Ding L; Peluffo G; Cohen O; Kales SC; Lal-Nag M; Rai G; Maloney DJ; Jadhav A; Simeonov A; Wagle N; Brown M; Meissner A; Sicinski P; Jaffe JD; Jeselsohn R; Gimelbrant AA; Michor F; Polyak K
Cancer Cell; 2018 Dec; 34(6):939-953.e9. PubMed ID: 30472020
[TBL] [Abstract][Full Text] [Related]
9. Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis.
Yoo J; Kim GW; Jeon YH; Kim JY; Lee SW; Kwon SH
Exp Mol Med; 2022 Dec; 54(12):2107-2117. PubMed ID: 36509829
[TBL] [Abstract][Full Text] [Related]
10. JARID1/KDM5 demethylases as cancer targets?
Taylor-Papadimitriou J; Burchell J
Expert Opin Ther Targets; 2017 Jan; 21(1):5-7. PubMed ID: 27882807
[No Abstract] [Full Text] [Related]
11. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
12. HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases.
Paroni G; Bolis M; Zanetti A; Ubezio P; Helin K; Staller P; Gerlach LO; Fratelli M; Neve RM; Terao M; Garattini E
Oncogene; 2019 Apr; 38(15):2675-2689. PubMed ID: 30538297
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting the Jumonji family: a potential new clinical approach to targeting aberrant epigenetic mechanisms.
Martinez ED; Gazdar AF
Epigenomics; 2016 Mar; 8(3):313-6. PubMed ID: 26918824
[No Abstract] [Full Text] [Related]
14. A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine.
Leadem BR; Kagiampakis I; Wilson C; Cheung TK; Arnott D; Trojer P; Classon M; Easwaran H; Baylin SB
Cancer Res; 2018 Mar; 78(5):1127-1139. PubMed ID: 29282222
[TBL] [Abstract][Full Text] [Related]
15. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Drewes G; Eagle R; Garton N; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Pemberton M; Rioja I; Seal GA; Shipley T; Singh O; Suckling CJ; Taylor J; Thomas P; Wilson DM; Lee K; Prinjha RK
J Med Chem; 2016 Feb; 59(4):1370-87. PubMed ID: 26771203
[TBL] [Abstract][Full Text] [Related]
16. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
17. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
18. Histone lysine demethylases in breast cancer.
Paolicchi E; Crea F; Farrar WL; Green JE; Danesi R
Crit Rev Oncol Hematol; 2013 May; 86(2):97-103. PubMed ID: 23266085
[TBL] [Abstract][Full Text] [Related]
19. KDM5 Lysine Demethylases in Pathogenesis, from Basic Science Discovery to the Clinic.
Zhang SM; Cao J; Yan Q
Adv Exp Med Biol; 2023; 1433():113-137. PubMed ID: 37751138
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
